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Myelodysplastic syndromes and acute myeloid leukemia exemplify the complexity of treatment allocation in
older patients as options range from best supportive care, non-intensive treatment (e.g. hypomethylating agents)
to intensive chemotherapy/hematopoietic cell transplantation. Novel metrics for non-disease variables are urgent-
ly needed to help define the best treatment for each older patient. We investigated the feasibility and prognostic
value of geriatric/quality of life assessments aside from established disease-specific variables in 195 patients aged
60 years or over with myelodysplastic syndromes/acute myeloid leukemia. These patients were grouped accord-
ing to treatment intensity and assessed. Assessment consisted of eight instruments evaluating activities of daily
living, depression, mental functioning, mobility, comorbidities, Karnofsky Index and quality of life. Patients with
a median age of 71 years (range 60-87 years) with myelodysplastic syndromes (n=63) or acute myeloid leukemia
(n=132) were treated either with best supportive care (n=47), hypomethylating agents (n=73) or intensive
chemotherapy/hematopoietic cell transplantation (n=75). After selection of variables, pathological activities of
daily living and quality of life/fatigue remained highly predictive for overall survival in the entire patient group
beyond disease-related risk factors adverse cytogenetics and blast count of 20% or over. In 107 patients treated
non-intensively activities of daily living of less than 100 (hazard ratio, HR 2.94), Karnofsky Index below 80 (HR
2.34) and quality of life/’fatigue’ of 50 or over (HR 1.77) were significant prognosticators. Summation of adverse
features revealed a high risk of death (HR 9.36). In-depth evaluation of older patients prior to individual treatment
allocation is feasible and provides additional information to standard assessment. Patients aged 60 years or over
with newly diagnosed myelodysplastic syndromes/acute myeloid leukemia and impairments in activities of daily
living, Karnofsky Index below 80%, quality of life/’fatigue’ of 50 or over, are likely to have poor outcomes. 
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ABSTRACT
Introduction 
In older patients with myelodysplastic syndromes (MDS)
or acute myeloid leukemia (AML), available treatment
options range from best supportive care (BSC) only, to non-
intensive chemotherapy or epigenetic therapy (hypomethy-
lating agents (HA): 5-azacytidine, decitabine) to potentially
curative, intensive treatment with standard induction
chemotherapy (IC) and consolidation including stem cell
transplantation (HCT). Although some advances in intensive
chemotherapeutic and transplant procedures have been made
(e.g. the introduction of reduced intensity conditioning,1,2
only a subgroup of patients aged over 60 years are considered
fit for induction, and the percentage drops for older individu-
als.3,4 Parameters for allocating treatment include both dis-
ease-specific parameters such as cytogenetics5 and new bio-
markers,6 as well as patient-specific variables such as numer-
ical age, performance status7 and comorbidities.8 Other
patient-related functional parameters likely considered by the
physicians making these decisions have not been sufficiently
characterized or quantified.9 Standardized tests to determine
and quantify the degree of fitness are now increasingly being
studied also in patients with myeloid neoplasias, lending sup-
port to their feasibility and valuable additional information10
to established models of risk prediction. In the latter context,
Krug et al. have constructed a strong prognosticator for com-
plete remission and early death based on data of 1,400 AML
patients (aged >60 years) treated intensively,11 including the
following parameters: body temperature, age, de novo
leukemia versus secondary leukemia, hemoglobin, platelet
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count, fibrinogen, serum lactate dehydrogenase.
Addressing tumor diversity is often referred to as personal-
ized cancer care. In contrast, we aimed to enhance data on
novel metrics for non-disease variables also reflecting
patient diversity. Therefore, we sought to delineate prog-
nostic variables within a battery of established functional
tests12 at baseline for elderly patients with MDS and AML.
The study did not seek to examine leukemia-specific vari-
ables or treatment effects on outcome. 
Design and Methods
Patients
Our study cohort included all consecutive patients aged 60 years
or over with an initial diagnosis of MDS and AML who presented
between March 2004 and June 2008 at the University Hospital
Freiburg Medical Center for treatment initiation, together with
patients seen at the University Medical Centers of Düsseldorf and
Dresden in 2006 and 2007. The local ethics committees and insti-
tutional review boards approved the study and all patients gave
their informed consent. Of the 195 patients, 130 participated in
clinical trials described in the Online Supplementary Appendix13-15
while 65 could not be included. 
Instruments 
We applied those instruments to assess patient-related factors
recommended for a comprehensive geriatric assessment12 at base-
line and again to survivors at six months (Online Supplementary
Appendix).13 To capture performance status (Karnofsky Index, KI),
each patient’s score was placed on a linear scale between 100 (nor-
mally active) and 0 (dead), summarizing their ability to perform
daily activities. To document the patient functional status, we
used assessments of ‘activities of daily living’ (ADL; Barthel Index)
and ‘instrumental activities of daily living’ (IADL). The Barthel
Index is a reliable assessment of a person's mobility and ability to
perform daily self-care tasks. According to the Hamburg classifica-
tion manual, total scores range from 0 to 100, with lower scores
indicating greater disability. The IADL scale measures eight com-
plex activities related to independent functioning. The total score
ranges from 0 to 8. Scores of less than the maximum in ADL and
IADL denote dependency.16-18
Data from medical records were extracted to identify and tabu-
late comorbidity according to both the Charlson19 and the
Hematopoietic Cell Transplantation (HCT)-specific Comorbidity
Indices (HCT-CI).20 Comorbidity describes any distinct additional
clinical entity that has existed or may occur during a patient’s clin-
ical course with an index disease (in this case, MDS/AML). The
Charlson Comorbidity Index (CCI) is the most commonly used in
oncology. Its main limitation is that the data address only the 19
conditions listed in the index. The HCT-CI presents a comorbidity
score adapted to the HCT setting. It assigns points for 17 common
medical conditions relevant in the transplant setting, resulting in a
score ranging from 0 to 29. 
Further geriatric syndromes were assessed by the ‘Get-up and
Go Test’, a brief assessment of gait and balance in older patients.
A score of over 20 seconds (s) implies a relevant impairment in
mobility.21 The Geriatric Depression Scale (GDS) is a self-reporting
questionnaire designed specifically to screen for depression in
older adults. A score higher than 5 suggests depression.22 The
Mini-Mental State Examination (MMSE) is the most widely used
instrument for assessing cognitive function, providing a total score
that reflects the individual’s level of cognitive function.23,24 To
assess QOL, we used the EORTC QLQ C-30 version 3.0, as this
has shown good psychometric utility in evaluating physical QOL
aspects and associated symptomatology.25-27 The questionnaire
contains one subscale for global quality of life, 5 functioning sub-
scales and 9 symptom subscales, with all subscales linearly con-
verted to a scale from 0 to 100. Minimum duration of the entire
assessment was 45 min.
In addition, we documented the following disease-related fac-
tors and laboratory data: percentage of bone marrow blasts (MDS
or AML, according to FAB classification), cytogenetics (in AML as
previously described),28,29 IPSS in MDS,30 peripheral blood leuko-
cytes and hemoglobin, serum LDH, serum creatinine, creatinine
clearance and serum albumin. To minimize the number of missing
values, we combined ‘adverse cytogenetics (AML)’ and ‘IPSS int-
2/high risk’ into one ‘poor risk cytogenetics/IPSS’ variable.
Statistical analysis
Data were analyzed using SAS software version 9.1. (SAS
Institute Inc., Cary, NC, USA). Cut-off points for single variables
were chosen after inspecting their distribution among all 195
patients such that a reasonable distribution into two groups
could be obtained, i.e. cut-off points near the median and round
numbers were used. Overall survival (OS) was calculated as the
time from start of therapy to death from any cause, with
patients alive being censored at the date last seen alive, and 6 HA
patients who finally received HCT being censored at time of
transplantation, respectively. The Kaplan-Meier method was
used to estimate OS rates over time, and the impact of possible
prognostic factors was analyzed with uni- and multivariate
Cox’s proportional hazards regression models stratified with
respect to therapy. The variable selection procedures Backward
Elimination (BE) and Forward Selection (FS) were applied.
Results are presented as estimated hazard ratios (HR) with
accompanying 95% confidence intervals (95% CI), where a
value of HR over 1 represents a higher risk for lower OS for the
respective patient group. 
Univariate analyses represent a first step in the evaluation of
the prognostic factors discussed here. We chose two different
approaches to construct a prognostic model based on geriatric
assessment/quality of life (GA/QOL) variables. First, in order to
investigate whether GA/QOL variables provide any prognostic
value beyond that of known prognostic factors, such as the per-
centage of bone marrow blasts, high-risk cytogenetics
(AML)/IPSS, performance status and comorbidities, we applied a
multivariate model with BE and FS to a set consisting of those
variables having a P value less than 0.1 in the univariate analysis.
Second, to select among the GA/QOL variables, BE and FS were
used for the complete set of 15 GA/QOL variables plus
Karnofsky Index, HCT-CI, and the Charlson Index. The result-
ing final model (which is the same for FS and BE) was used to
construct a model in which variables remaining in the final
model at a significance level of 5% were weighed according to
their regression coefficient rounded to the nearest integer.
According to the Kaplan-Meier estimation of OS for each score
value, risk groups were then classified. As the analysis is based
on a population of patients receiving different treatments, the
analysis was carried out for subgroups according to treatment.
Results 
Baseline application of the geriatric and quality 
of life assessment 
Between January 2004 and June 2008, 223 patients with
MDS or AML were prospectively assessed at the start of
their respective treatment (median time from diagnosis to
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first specific treatment 40 days, range 5-200 days).
Twenty-eight patients were excluded because of missing
data at baseline or on follow up, and incapacity to sign
informed consent; therefore, 195 patients were included in
the statistical analysis. Median follow up was 461 days. 
Patients’ characteristics are listed in Table 1. Briefly,
approximately 25% were allocated according to their
physicians' recommendations or their own wish to
receive only BSC (consisting of transfusions, cytoreduc-
tion with hydroxyurea, and antibiotics) and approximate-
ly 38% to either HA or standard IC (two-thirds of the lat-
ter proceeded to allografting). A third of the patients were
diagnosed with MDS and two-thirds with AML (FAB).
Median age was 71 years. Of all patients, 67 were
impaired in activities of daily living (ADL<100) and only
slightly more than 50% had a performance status
(Karnofsky Index) over 80. 
Cognitive impairment or signs of overt depression were
present in 17 and 28 patients, respectively, and 108
patients required more than 20 s for the ‘Get-up and Go
Test’ (median 21 s) indicating an increase in the risk of
falls. Patients had a mean of 0.96 comorbidity index points
according to the Charlson Index and 2.5 according to the
HCT-CI (Sorror), respectively. The prognostic factor
analysis according to the risk index defined by Wheatley
et al.31 (cytogenetic group, age, white blood count, per-
formance status and type of AML, i.e. de novo, secondary)
reveals that the majority of trial patients (63.6%) were in
the poor risk group and that none of the non-intensively
treated patients were in the good risk group (Table 1). 
There was a significant difference in initial GA/QOL
assessment results among the different treatment groups,
with IC patients being markedly younger and significantly
less often affected by geriatric symptoms. (Table 1, and
Online Supplementary Table S1).
Among variables which appeared to be of prognostic
importance (P<0.1) in univariate analyses, pathological
ADL and increased ‘fatigue’ (≥50 by EORTC QLQ-C30)
remained highly predictive for overall survival in the entire
patient group (BSC, HA, IC/HCT) beyond the established,
disease-related risk factors such as poor risk
cytogenetics/IPSS and bone marrow blast count of 20% or
over.  Furthermore, these parameters differentiated con-
vincingly between high- and low-risk patients treated
with BSC or HA, with those with a higher score in
‘fatigue’ and ADL impairments having shorter overall sur-
vival. To focus on a homogeneous cohort, and to avoid the
confounding effect of treatment, we subjected the
GA/QOL values of the 107 patients treated non-intensive-
ly (BSC and HA) to further statistical analyses. 
Results of the univariate analysis of all tested variables
in patients treated non-intensively (n=107) are shown in
Table 2. We performed multivariate analysis after variable
selection. The final model that included the established
disease-related risk factors ‘poor risk cytogenetics/IPSS’
and ‘bone marrow blasts’ is shown in Table 3. The final
model (which included only GA/QOL variables) revealed
the strong prognostic information of impaired perform-
ance defined as Karnofsky Index below 80, ADL below
100 and ‘fatigue’ of 50 or over by EORTC QLQ C-30, as
shown in Table 4. These parameters differentiated strong-
ly between patients treated with BSC alone or HA, with
those showing signs of dependence (ADL, Karnofsky
Index), or with a fatigue score of 50 or over indicating
shorter overall survival (Figure 1A-F). 
Application of a risk assessment score 
To obtain a simple risk assessment score in patients
treated non-intensively which predicted a decrease in
overall survival, we combined the variables ‘performance
status’ (Karnofsky Index), ‘activities of daily living’ (ADL)
and ‘QOL/fatigue’. Because the regression coefficients
were similar in size, no further weighting was necessary.
Both disease-related parameters (bone marrow blasts
≥20% and poor risk cytogenetics/IPSS) that had revealed
no significant association (Fisher's Exact Test; Online
Supplementary Table S2) were not included in the final
model, as we sought parameters not primarily reflecting
disease status.
Application of this score to patients treated without cur-
ative intent (BSC and HA) is shown in Figure 2A. Patients
considered at low risk (with 0 risk features) had signifi-
cantly longer overall survival (median 774 days) than
patients with 1 or 2 points (median 231 days) having inter-
mediate risk, and than the high-risk group (median 51
days) with three risk features (P<0.0001). In the next step,
the score was applied to patients that had been allocated
to the three different treatment categories. As shown in
Figure 2B and C, this score highly discriminates the out-
come in patients allocated to either BSC and HA, respec-
tively. Application of the score to IC/HCT patients is
shown in Figure 2D. 
Table 5 shows some associations between the risk
assessment score and established scores, where the major-
ity of patients are found to be within the poor prognosis
risk group according to Wheatley et al.  
Discussion
A rationale for incorporating a geriatric assessment into
the management of older cancer patients is to obtain addi-
tional objective, quantifiable and reproducible information
on the individual beyond the physician's clinical judgment
alone.32,33 These patient-specific data have recently been
more closely considered when estimating treatment toler-
ance and outcome. Assessments are recommended for
screening purposes, and to eventually be followed by
focused interventions in a geriatric oncology setting;34,35
yet there is still no firm evidence of the clinical impact of
this approach with regard to its predictive value on mor-
tality.36 However, an association has been reported
between GA outcomes and treatment allocation in elderly
cancer patients.37
In this study, patients were prospectively assessed by a
multidimensional geriatric and QOL assessment to
demonstrate its applicability in a multicenter setting (a
prerequisite for its further application in larger trials).
Furthermore, it was our aim to investigate whether elderly
MDS/AML patients with differing prognoses can be iden-
tified based on patient-related information. While highly
valuable, the GA entails administering a battery of instru-
ments that is resource-intensive. This reinforced our
efforts to define the strongest prognosticators to briefly
objectify what so far has been a largely subjective matter
of treatment allocation.38
Initial GA/QOL values differed significantly among the
three treatment groups. As expected, patients ‘fit for
induction allografting’ displayed the best result. This con-
firms that the adopted criteria may already be influencing
the rigorous therapeutic decision-making process, and that
B. Deschler et al.
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their systematic incorporation may prove useful and even
advisable in selecting patients fit for treatment in terms of
risk and future benefit. This is a much-needed step toward
designing the best care for vulnerable patients. 
Throughout our investigations, parameters consistently
retained their highly significant prognostic impact in the
BSC and HA groups, while their prognostic effect was
weaker in the ‘fitter’ and younger intensively treated
patients. We assume that this effect is due to the fact that
patients receiving IC/HCT showed significantly better
overall survival than those allocated to BSC or HA only,
resulting in less prominent hazard ratios. Also, the deci-
sion to treat intensively may be primarily influenced by
the patient's assumed ability to tolerate treatment, so that
future prospective trials will need to consider treatment-
related mortality as a primary outcome measure in the
IC/HCT group. Interestingly, 11 patients treated intensive-
ly displayed a ‘high-risk situation’ with regards to their
performance, ADL and ‘fatigue’ scores, and fared relative-
ly well (Figure 2D). After thorough revision of their clinical
course, we hypothesize that the assumption of reversibil-
ity of frailty (taken to be caused by the disease and not
only by age or comorbidities) by intensive treatment
prompted the therapeutic decision. Further studies should
investigate larger patient numbers and develop proper
tools to distinguish between impairments that are due to
leukemia as opposed to general or pre-existing limitations. 
This study did not attempt to compare the different
treatment strategies, leaving unsolved the question as to
whether IC/HCT actually is a better treatment option for
the majority of patients, or whether further unknown or
unquantifiable selection factors (e.g. doctor's bias) are
great enough to explain differences in survival. Ultimately,
this question can only be solved by a randomized con-
trolled treatment study the feasibility of which must take
into account numerous ethical concerns. Such studies
should, however, include the most relevant patient-specif-
ic criteria. To rule out the confounding factors of treat-
ment, we focused on patients undergoing non-intensive
treatment only, to identify those variables that were inde-
QOL and outcome in elderly MDS and AML patients 
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Table 1. Patients’ characteristics.
Demographic or BSC (n=47) HA (n=73) IC (n=75) Total  (n=195)
clinical characteristic N. of patients % N. of patients % N. of patients % N. of patients %
Sex
male 33 70.2 53 72.6 46 61.3 132 67.7
female 14 29.8 20 27.4 29 38.7 63 32.3
MDS 31 66.0 20 27.0 12 16.0 63 32.0
IPSS low/int-1 16 34 2 2.74 1 1.3 19 9.7
IPSS int-2/high 9 19.1 16 21.9 8 10.7 33 16.9
Cytogenetics not available 6 12.8 2 2.7 3 4.0 11 5.6
AML 16 34.0 53 73.0 63 84.0 132 68.0
Cytogenetics available 12 25.5 51 70.3 52 69.3 115 59.3
Adverse cytogenetics 4 8.5 16 21.9 13 17.3 33 16.9
Cytogenetics not available 4 8.5 2 2.7 11 14.7 17 8.7
Median OS (days) 307 231 not reached
Age, years
Median 75 74 68 71 
Range 64-87 60-82 60-78 60-87
Karnofsky Index
Median 70 80 80 80
Range 20-90 30-80 40-90 20-90
EORTC QLQ-C30 Fatigue
Median 53.3 66.6 44.3 53.3
Range 0-100 0-100 0-100 0-100
ADL (Barthel Index)
Median 100 100 100 100
Range 20-100 55-100 25-100 20-100
HCT-CI (Sorror)
Median 3 2 2 2
Range 0-7 0-7 0-8 0-8
BSC (n=17) HA (n=56) IC (n=67) Total (n=140)
Wheatley Score
Median 11 10 8 10
Range 8-14 7-15 5-15 5-15
Wheatley Risk Group N. of patients % N. of patients % N. of patients % N. of patients %
good (Score: 4-6) 0 0 0 0 10 14.9 10 7.1
standard (Score: 7-8) 3 17.7 14 25 24 35.8 41 29.3
poor (Score: 9+) 14 82.3 42 75 33 49.3 89 63.6
AML: acute myeloid leukemia; MDS: myelodysplastic syndromes; IPSS: international prognostic scoring system; BSC: best supportive care; HA: hypomethylating agents; IC/HCT:
induction chemotherapy/hematopoietic cell transplantation. 
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pendent patient-related prognostic parameters suited to
developing a prognostic model. In the multivariate analy-
sis of overall survival in 107 patients, only impairments in
performance status, in activities of daily living (ADL) and
the symptom item ‘fatigue’ from the EORTC QOL-C30
were retained as independent prognostic factors of overall
survival, in addition to the known MDS/AML-related risk
factors poor risk cytogenetics/IPSS and bone marrow
blasts of 20% or over. Therefore, the basic information
reflecting a patient's functionality (KI, ADL) and QOL
strongly indicate vulnerability and complement the key
clinical parameters that have until now influenced treat-
ment decision-making (i.e. numerical age, percentage of
blast or cytogenetics). Impairments in the more sophisti-
cated parameters (IADL, MMSE, ‘Get-Up-and-Go Test’)
may on the contrary represent a distinct individual state
B. Deschler et al.
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Figure 1. Overall survival (OS) of non-intensively treated patients according to the geriatric assessment results for activities of daily living
(ADL) (A,B), performance status (Karnofsky Index <80) (C,D), and ‘fatigue’ <50 (E,F). (A). Patients receiving best supportive care only. (B).
Patients receiving hypomethylating agents. (C). Patients receiving best supportive care only. (D). Patients receiving hypomethylating agents.
(E). Patients receiving best supportive care only. (F). Patients receiving hypomethylating agents.
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and may, therefore, be more suited to focused geriatric
screening and intervention.  
Focusing on the single most important risk parameters
of our study, the Karnofsky Index is as frequently used to
describe performance as is the ECOG performance status.
Both show excellent correlation and interconversion. Only
recently, the Karnofsky Index has been shown to identify
patients with at least two abnormalities on the GA.39 To
reassess our findings on the prognostic power of perform-
ance status, we compared data with those of a random-
ized phase III EORTC trial of low-dose decitabine versus
BSC in elderly patients with intermediate- or high-risk
myelodysplastic syndrome (MDS) ineligible for intensive
chemotherapy.40 These independent data of 137 evaluable
patients confirmed the prognostic value of PS (HR 2.70;
P=0.005 for PS<80) as shown in Online Supplementary
Tables S3 and S4.  
The ADL or Barthel Index comprises 10 activities of
daily living with different levels of dependency.16 It has
been suggested that this is more sensitive than the
Karnofsky Index for assessing physical functioning in
some patient groups but it has not yet been investigated as
a potential prognosticator in patients with hematologic
neoplasias.41 As opposed to the performance indices that
reflect the physicians' estimation, ADL requires detailed
information in a standardized questionnaire. Interestingly,
despite correlations between ADL and Karnofsky Index,
ADL does provide additional information, as both param-
eters were retained in our multivariate analysis. This easi-
ly obtainable index, used frequently in daily practice to
QOL and outcome in elderly MDS and AML patients 
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Table 2. Univariate analysis of tested variables (non-intensive treat-
ment groups; n=107). Hazard Ratios (HR) and confidence intervals
(95% CI) were estimated using Cox’s proportional hazards regression
models. Categorical variables were applied.
Parameter Hazard Ratio (95%CI) P value
Patient-related factors
Karnofsky Index <80% 4.24 (2.41 , 7.46) <0.0001
ADL (Barthel Index) <100 4.00 (2.39 , 6.62) <0.0001
Timed "up+go" test >30 sec. 3.30 (2.00 , 5.42) <0.0001
Instrum. activities of daily living 1.97 (1.22 ,  3.18) 0.006
Mini mental state (MMS) examination<28 1.92 (1.18 , 3.11) 0.008
HCT-CI (Sorror) comorbidities≥3 1.67 (1.05 , 2.68) 0.03
Charlson comorbidities >1 1.64 (1.00 , 2.67) 0.05
Timed "up+go" test >20 sec. 1.41 (0.85 , 2.33) 0.19
HCT-CI (Sorror)  comorbidities ≥1 1.21 (0.64 , 2.25) 0.56
Age ≥73 years 1.14 (0.71 , 1.82) 0.59
Geriatric Depression Scale (GDS) ≥6 1.08 (0.53 , 2.18) 0.84
EORTC QLQ-C30 domains
Physical functioning<50 3.13 (1.89 , 5.18) <0.0001
Fatigue ≥50 3.03 (1.77 , 5.17) <0.0001
Role functioning<50 2.68 (1.61 , 4.44) 0.0001
Cognitive functioning<50 2.58 (1.27 , 5.23) 0.009
Global QOL<50 2.44 (1.51 , 3.92) 0.0002
Emotional functioning<50 1.86 (1.15 , 3.0) 0.01
Nausea/vomiting≥0 1.70 (1.02 , 2.81) 0.04
Pain≥0 1.67 (1.05 , 2.65) 0.03
Social functioning <50 1.64 (0.36 , 1.03) 0.06
Dyspnea≥0 1.25 (0.75 , 2.08) 0.39
Disease-related factors
Bone marrow blasts >20% 4.06 (2.21 , 7.45) <0.0001
Poor risk cytogenetics/IPSS 2.03 (1.21 , 3.39) 0.007
WBC >3x109/L 1.42 (0.88 , 2.28) 0.15
Table 3. Multivariate analysis results for parameters with P<0.1 in uni-
variate analysis, including established disease-related risk factors
"poor risk cytogenetics/IPSS" and blasts (n=107), using a dummy
variable "Risk Status unknown" in 14 cases. 
Parameter Hazard Ratio (95%CI) P value
BM Blasts: > 20% vs. <=20% or unknown 3.39 (1.82, 6.33) 0.0001
Cytogenetics/IPSS: Poor vs. low risk 3.04 (1.69, 5.46) 0.0002
ADL (Barthel Index): <100 vs. 100 2.60 (1.37, 4.93) 0.004
Karnofsky Index: <80 vs >=80 2.14 (1.10, 4.15) 0.02
HCT-CI (Sorror): ≥3 vs.<3 1.98 (1.14, 3.44) 0.02
EORTC QLQ-C30 fatigue: ≥50 vs. <50 1.82 (1.02, 3.23) 0.04
Cytogenetics/IPSS: unknown vs. low risk 1.86 (0.69, 4.98) 0.22
Table 4. Multivariate analysis results for GA/QOL parameters only, with
P<0.1 in univariate analysis, excluding risk factors "poor risk cytoge-
netics/IPSS" and blasts (n=107). Remaining variables define "Risk
Assessment Score".
Parameter                                          Hazard Ratio (95%CI)      P value
Karnofsky Index<80                                       2.45 (1.23, 4.87)                 0.01
ADL (Barthel Index) <100                            2.10 (1.13, 3.89)                 0.02
EORTC QLQ-C30 Fatigue ≥50                      2.09 (1.17, 3.71)                 0.01
Table 5. Relationship of scores. 
HCT-CI  (Sorror)
Risk assessment score BSC/HA (n=107) IC (n=75) Total (n=182)
Median Range Median Range Median Range
Good (score 0) 1.5 0-6 1.5 0-7 1.5 0-7
Standard (score 1-2) 2 0-7 2.5 0-8 2.0 0-7
Poor (score 3) 3 0-7 3.0 0-6 3.0 0-7
Wheatley Score
Risk assessment score BSC/HA (n=73) IC (n=67) Total (n=140)
Median Range Median Range Median Range
Good (score 0) 9.5 9-14 8.5 5-12 9 5-14
Standard (score 1-2) 10.5 10.5-15 9.5 6-15 10 6-15
Poor (score 3) 10 10-15 7 6-10 10 6-15
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estimate and communicate degrees of dependence,
emerges in this study as having additional value in objec-
tifying decision-making processes. In agreement with this,
a recent investigation on the impact of a geriatric assess-
ment in treatment decision-making in elderly patients
revealed that the ADL’s value correlates with treatment
allocation (non-intensive care vs. intensive treatment
efforts).37
Several studies have shown baseline QOL parameters to
be independent prognostic factors in different malignan-
cies42-45 underscoring the assumption that QOL scales add
prognostic information to clinical measures and predict
survival.46 Patient ratings of physical symptoms (i.e.
‘fatigue’), physical functioning and global health
status/QOL have repeatedly been the best predictors of
survival.45,47 In this context, Oliva et al. reported a study on
elderly AML patients in which QOL physical functioning
was of prognostic relevance yet, somewhat surprisingly,
did not correlate to the physician-assessed ECOG per-
formance status.48 While the item ‘fatigue’ has been
shown to be prognostically relevant in several different
malignant diseases,47,49-51 so far only hypotheses to explain
the mechanisms underlying the association between
reported data on patient health status and duration of sur-
vival have been proposed.52 ‘Fatigue’ is a patient-reported
outcome and multi-faceted concept including both mental
and physical components whose critical domains have not
been sufficiently standardized and for which several scales
have been developed.53 Despite these shortcomings, we
believe that further investigation of this extremely debili-
tating symptom observed in many if not all cancer
patients is useful for optimizing patient care.
When comparing our score to established risk assess-
ment scores (i.e. comorbidity score by Sorror, risk index
by Wheatley), we found that, despite some associations,
independent and complementary information could be
obtained. We, therefore, suggest that the scores do actual-
ly measure different aspects of patient- and disease-specif-
ic factors. Possibly, the estimation of functionality might
display an increasing relevance in patients treated non-
intensively who are, on average, older, while parameters
calculated in the established scores may be even more rel-
evant in younger, intensively treated patients. Future stud-
ies may reveal whether the scores can complement each
other. 
Our study has several limitations. First, the assessments
were all performed by a small number of trained physi-
cians raising the possibility that a bias could have been
introduced. However, the instruments were, whenever
possible, patient self-administered. Second, our patient
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Figure 2. Overall survival (OS) according to frailty score risk groups and treatment (evaluable patients) (A). All patients treated non-intensively
(n=107). (B). Patients receiving best supportive care only (n=41). (C). Patients receiving hypomethylating agents (n=66). (D). Patients receiv-
ing induction chemotherapy/hematopoietic cell transplantation (n=75).
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population was heterogeneous and included patients with
different treatment intensities. However, this is an obser-
vational study that sought to determine the prognostic
value of the QOL/GA at baseline. The study did not seek
to examine disease-specific variables or treatment effects
on outcomes and, therefore, risk prediction models were
carried out according to treatment. The resulting risk
assessment score revealed the best prognostic potency for
patients treated non-intensively and will need further val-
idation.  
In conclusion, this study supports the systematic,
prospective use of geriatric and QOL assessments as
important additional tools in clinical evaluations. It raises
awareness of relevant issues of QOL as well as objective
functional capabilities that might otherwise go unnoticed.
Some scales within the comprehensive GA showed weak
prognostic impact and strong correlations to other param-
eters, suggesting the use of a brief and simplified tool. In
particular, patients’ functional and symptom variables as
measured by Karnofsky Index, ADL and ‘fatigue’ appear
to possess prognostic strength similar to that of
MDS/AML-related risk factors, such as poor risk cytoge-
netics/IPSS and blast counts. Patients aged 60 years or over
with newly diagnosed MDS/AML and a Karnofsky Index
below 80%, EORTC QOL fatigue of 50 or over, and
impairments in ADL are likely to have poor outcomes.
Prospective studies to validate our findings are well under-
way. Finally, data on a validated unique score reflecting
the reserves or vulnerability of this special patient popula-
tion are needed to incorporate them into algorithms for
therapeutic decision-making to complement established
disease-specific risk factors; a very worthwhile step
toward defining the best treatment option for each older
patient. 
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